EU approves Sanofi and Regeneron's dupilumab in eczema

PARIS (Reuters) - The European Commission approved Regeneron Pharmaceuticals' and Sanofi's key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said on Thursday.